Alkermes plc
ALKSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframeAlkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in. The $7.63B market capitalization puts ALKS squarely in mid-cap range for its industry. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Market Cap
$7.63B
Beta
0.26
P/E (TTM)
119.71
P/E (Fwd)
24.88
EPS (TTM)
$0.38
EPS (Fwd)
$1.83
ROE
3.9%
ROA
4.2%
Cash
$656.6M
Total Debt
$1.57B
Free CF
$153.4M
52W Change
71.2%
Annual Financials
Cash vs Debt
Where ALKS stands vs its 150-day and 200-day moving averages
As of the July 30, 2026 close, ALKS finished 30.33% above its 150-day moving average ($37.09) and 36.86% above its 200-day moving average ($35.32). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALKS overbought or oversold?
At the July 30, 2026 close, ALKS's RSI(14) was 24.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alkermes plc carries $1.57B in total debt against $656.6M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $153.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 3.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $1.11B to $1.48B.
The relatively low beta of 0.26 suggests ALKS is a less volatile holding compared to the broader index. At over 50x earnings, ALKS carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing ALKS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.